These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 1313384

  • 1. Clinical evaluation of tissue plasminogen activator (t-PA) levels in patients with liver diseases.
    Okabe K, Kato I, Sato S, Kashiwabara T, Furuta S, Sato H, Tanikawa K, Kumashiro R, Kanayama M.
    Gastroenterol Jpn; 1992 Feb; 27(1):61-8. PubMed ID: 1313384
    [Abstract] [Full Text] [Related]

  • 2. Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease.
    Leiper K, Croll A, Booth NA, Moore NR, Sinclair T, Bennett B.
    J Clin Pathol; 1994 Mar; 47(3):214-7. PubMed ID: 8163691
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis.
    Tran-Thang C, Fasel-Felley J, Pralong G, Hofstetter JR, Bachmann F, Kruithof EK.
    Thromb Haemost; 1989 Sep 29; 62(2):651-3. PubMed ID: 2510345
    [Abstract] [Full Text] [Related]

  • 5. [Studies on the mechanism of hyperfibrinolysis in liver cirrhosis--changes of plasma t-PA, PAI-1 and active PAI-1 levels in liver cirrhosis].
    Matsuura R, Soma M, Maeda Y, Kasakura S.
    Rinsho Byori; 1995 Dec 29; 43(12):1256-60. PubMed ID: 8569037
    [Abstract] [Full Text] [Related]

  • 6. PAI-1, t-PA and circulating hTERT DNA as related to virus infection in liver carcinogenesis.
    Divella R, Lacalamita R, Tommasi S, Coviello M, Daniele A, Garrisi VM, Abbate I, Simone G, Gadaleta C, Paradiso A, Quaranta M.
    Anticancer Res; 2008 Dec 29; 28(1A):223-8. PubMed ID: 18383849
    [Abstract] [Full Text] [Related]

  • 7. [Tissue-type plasminogen activator and its inhibitor (PAI-1) in plasma in cases of non-insulin-dependent diabetes mellitus (NIDDM)].
    Jokaji H, Asakura H, Saito M, Uotani C, Kumabashiri I, Morishita E, Yamazaki M, Matsuda T.
    Nihon Ronen Igakkai Zasshi; 1990 Nov 29; 27(6):699-705. PubMed ID: 2127812
    [Abstract] [Full Text] [Related]

  • 8. Elevated urokinase-type plasminogen activator plasma levels are associated with deterioration of liver function but not with hepatocellular carcinoma.
    Sato S, Higashi T, Ouguchi S, Hino N, Tsuji T.
    J Gastroenterol; 1994 Dec 29; 29(6):745-50. PubMed ID: 7874270
    [Abstract] [Full Text] [Related]

  • 9. Serum PAI-1 and PAI-1 4G/5G Polymorphism in Hepatitis C Virus-Induced Cirrhosis and Hepatitis C Virus-Induced Hepatocellular Carcinoma Patients.
    El Edel RH, Essa ES, Essa AS, Hegazy SA, El Rowedy DI.
    Viral Immunol; 2016 Nov 29; 29(9):510-515. PubMed ID: 27459171
    [Abstract] [Full Text] [Related]

  • 10. Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocellular carcinoma.
    Mukozu T, Nagai H, Matsui D, Kanekawa T, Sumino Y.
    Anticancer Res; 2013 Mar 29; 33(3):1013-21. PubMed ID: 23482775
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of tissue plasminogen activator activity by aspirin in vivo and its relationship to levels of tissue plasminogen activator inhibitor antigen, plasminogen activator and their complexes.
    Levin RI, Harpel PC, Harpel JG, Recht PA.
    Blood; 1989 Oct 29; 74(5):1635-43. PubMed ID: 2529003
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Diagnostic efficacy of plasma urokinase-type plasminogen activator and plasminogen activator inhibitor-2 in differentiation of hepatocellular carcinoma from cirrhosis.
    Song KS, Lee A, Choi JR, Kwon OH.
    Thromb Haemost; 1995 Sep 29; 74(3):864-7. PubMed ID: 8571313
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Circulating intercellular adhesion molecule-1 in chronic liver disease and hepatocellular carcinoma.
    Huang YS, Wu JC, Chan CY, Chao Y, Chang FY, Lee SD.
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Aug 29; 62(8):487-95. PubMed ID: 10462824
    [Abstract] [Full Text] [Related]

  • 20. Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma.
    Chandler WL, Trimble SL, Loo SC, Mornin D.
    Blood; 1990 Sep 01; 76(5):930-7. PubMed ID: 2118399
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.